The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells

  • Authors:
    • Alejandro Schcolnik‑Cabrera
    • Alma Chavez‑Blanco
    • Guadalupe Dominguez‑Gomez
    • Mandy Juarez
    • Donna Lai
    • Sheng Hua
    • Armando R. Tovar
    • Jose Diaz‑Chavez
    • Alfonso Duenas‑Gonzalez
  • View Affiliations

  • Published online on: July 9, 2020     https://doi.org/10.3892/ol.2020.11838
  • Pages: 3053-3060
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer upregulates glycolysis, glutaminolysis and lipogenesis, and induces a catabolic state in patients. The concurrent inhibition of both tumor anabolism and host catabolism, and the energetic consequences of such an approach, have not previously been fully investigated. In the present study, CT26.WT murine colon cancer cells were treated with the combination of anti‑anabolic drugs orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine (DON; OLD scheme), which are inhibitors of the de novo synthesis of fatty acids, glycolysis and glutaminolysis, respectively. In addition, the effects of OLD scheme sumplemented with the combination of anti‑catabolic compounds, namely growth hormone, insulin and indomethacin (GII scheme), were also evaluated. The effects of the compounds used in combination on CT26.WT cell viability, clonogenicity and energetic metabolism were assessed in vitro. The results demonstrated that the anti‑anabolic approach reduced cell viability, clonogenicity and cell cycle progression, and increased apoptosis. These effects were associated with decreased oxidative phosphorylation, glycolysis and fuel flexibility. Furthermore, the anti‑catabolic scheme, alone or supplemented with anti‑anabolic compounds, did not favor tumor growth. These findings indicated that the simultaneous pharmacological inhibition of tumor anabolism and host catabolism exhibits antitumor effects that should be further evaluated.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Schcolnik‑Cabrera A, Chavez‑Blanco A, Dominguez‑Gomez G, Juarez M, Lai D, Hua S, Tovar AR, Diaz‑Chavez J and Duenas‑Gonzalez A: The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncol Lett 20: 3053-3060, 2020
APA
Schcolnik‑Cabrera, A., Chavez‑Blanco, A., Dominguez‑Gomez, G., Juarez, M., Lai, D., Hua, S. ... Duenas‑Gonzalez, A. (2020). The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncology Letters, 20, 3053-3060. https://doi.org/10.3892/ol.2020.11838
MLA
Schcolnik‑Cabrera, A., Chavez‑Blanco, A., Dominguez‑Gomez, G., Juarez, M., Lai, D., Hua, S., Tovar, A. R., Diaz‑Chavez, J., Duenas‑Gonzalez, A."The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells". Oncology Letters 20.3 (2020): 3053-3060.
Chicago
Schcolnik‑Cabrera, A., Chavez‑Blanco, A., Dominguez‑Gomez, G., Juarez, M., Lai, D., Hua, S., Tovar, A. R., Diaz‑Chavez, J., Duenas‑Gonzalez, A."The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells". Oncology Letters 20, no. 3 (2020): 3053-3060. https://doi.org/10.3892/ol.2020.11838